AUSTRALIAN PRODUCT INFORMATION

NAME OF THE MEDICINE

TYPHIM Vi™
Purified polysaccharide capsule of Salmonella typhi (Ty 2 strain)

DESCRIPTION

TYPHIM Vi is a sterile solution, prepared from the purified polysaccharide capsule of Salmonella typhi (Ty 2 strain). The purified polysaccharide capsule is diluted in isotonic buffer solution which contains phenol as preservative. The vaccine is a clear, colourless solution. Each single dose of 0.5 mL is formulated to contain 0.025 milligrams of purified capsular polysaccharide, preserved with phenol (less than 1.25 mg per dose). The isotonic buffer solution contains 4.15 mg of sodium chloride, 0.065 mg of sodium phosphate dibasic dihydrate and 0.023 mg of sodium phosphate monobasic.

The manufacture of this product includes exposure to bovine materials. No evidence exists that any case of vCJD (considered to be the human form of bovine spongiform encephalopathy) has resulted from the administration of any vaccine product.

PHARMACOLOGY

Mechanism of Action

This vaccine contains purified Vi capsular polysaccharide of Salmonella typhi (Ty 2 strain). Antibody sero-conversion is observed in over 90% of recipients 28 days after a single dose. Antibodies appear after approximately 7 to 15 days and reach peak values around 28 to 35 days after the injection. Persistence of the antibody response is at least 3 years. Protection is achieved in 60-80% of vaccinees during the first year and in 50-77% during the next 2 years.

CLINICAL TRIALS

Immunogenicity

Two formulations were utilized in studies of the typhoid Vi polysaccharide vaccine. These included the liquid formulation which is identical to TYPHIM Vi and lyophilised formulation. The protective efficacy of each of these formulations of the typhoid Vi polysaccharide vaccine was assessed independently in two trials conducted in areas where typhoid fever is endemic. A single intramuscular dose of 25 μg was used in these efficacy studies. A randomised double-blind controlled trial with TYPHIM Vi (liquid formulation) was conducted in five villages west of Katmandu, Nepal. There were 6,908 vaccinated subjects: 3,454 received TYPHIM Vi and 3,454
in the control group received a 23-valent pneumococcal polysaccharide vaccine. Of the 6,908 subjects, 6,439 subjects were in the target population of 5 to 44 years of age. In addition, 165 children ages 2 to 4 years and 304 adults over 44 years of age were included in the study. The overall protective efficacy of TYPHIM Vi was 74% (95% confidence interval (CI): 49% to 87%) for blood culture confirmed cases of typhoid fever during 20 months of post-vaccination follow-up.

The protective efficacy of the typhoid Vi polysaccharide vaccine, lyophilised formulation, was evaluated in a randomised double-blind controlled trial conducted in South Africa. There were 11,384 vaccinated children 5 to 15 years of age; 5,692 children received the Vi capsular polysaccharide vaccine and 5,692 in the control group received meningococcal polysaccharide (Groups A+C) vaccine. The protective efficacy for the Vi capsular polysaccharide (lyophilised formulation) group for blood culture confirmed cases of typhoid fever was 55% (95% CI: 30% to 70%) overall during 3 years of post-vaccination follow-up, and was 61%, 52% and 50%, respectively, for years 1, 2, and 3. Vaccination was associated with an increase in anti-Vi antibodies as measured by radioimmunoassay (RIA) and enzyme-linked immunosorbent assay. Antibody levels remained elevated at 6 and 12 months post-vaccination.

An increase in serum anti-capsular antibodies is thought to be the basis of protection provided by TYPHIM Vi. However, a specific correlation of post-vaccination antibody levels with subsequent protection is not available and the level of Vi antibody that will provide protection has not been determined. Also, limitations exist for comparing immunogenicity. In endemic regions (Nepal, South Africa, Indonesia) where trials were conducted, pre-vaccination geometric mean antibody levels suggest that infection with \( S. typhi \) has previously occurred in a large percentage of the vaccinees. In these populations, specific antibody levels increased four-fold or greater in 68% to 87.5% of older children and adult subjects following vaccination. For 43 persons 15 to 44 years of age in the Nepal pilot study, geometric mean specific antibody levels pre- and 3 weeks post-vaccination were, respectively, 0.38 and 3.68 \( \mu \)g antibody/mL by RIA; 79% had a four-fold or greater rise in Vi antibody levels.

Immunogenicity and safety trials were conducted in a racially mixed US population. A single dose of TYPHIM Vi vaccine induced a four-fold or greater increase in antibody levels in 88% and 96% of this adult population for 2 studies, respectively, following vaccination.

A double-blind randomised controlled trial testing the safety and immunogenicity of TYPHIM Vi was performed in 175 Indonesian children. The percentage of 2- to 5-year-old children achieving a four-fold or greater increase in antibody levels at 4 weeks post-vaccination was 96.3% (52/54) (95% CI: 87.3% to 99.6%), and in the study subset of 2-year-old children was 94.4% (17/18) (95% CI: 72.7% to 99.9%). The geometric mean levels (\( \mu \)g antibody/mL, by RIA) for the 2-to 5-year-old children and the subset of 2-year-olds were, respectively, 5.81 (4.36 to 7.77) and 5.76 (3.48 to 9.53).

In an U.S. Reimmunisation Study, adults previously immunised with TYPHIM Vi in other studies were reimmunised with a 25 \( \mu \)g dose at 27 or 34 months after the
primary dose. Data on antibody response to primary immunisation, decline following primary immunisation, and response to reimmunisation are presented in Table 1. Antibody levels attained following reimmunisation at 27 or 34 months after the primary dose were similar to levels attained following the primary immunisation. This response is typical for a T-cell independent polysaccharide vaccine in that reimmunisation does not elicit higher antibody levels than primary immunisation.

**TABLE 1: US STUDIES IN 18 TO 40-YEAR-OLD ADULTS: KINETICS AND PERSISTENCE OF Vi ANTIBODY* RESPONSE TO PRIMARY IMMUNIZATION WITH TYPHIM Vi, AND RESPONSE TO REIMMUNIZATION AT 27 OR 34 MONTHS.**

<table>
<thead>
<tr>
<th>GROUP 1&lt;sup&gt;a&lt;/sup&gt;</th>
<th>N</th>
<th>Level*</th>
<th>95% CI</th>
<th>PreDOSE 1</th>
<th>1 Month</th>
<th>11 Months</th>
<th>18 Months</th>
<th>27 Months</th>
<th>34 Months</th>
<th>1 Month POST-REIMMUNIZATION&lt;sup&gt;e&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>43</td>
<td>0.19</td>
<td>(0.14-0.26)</td>
<td>43</td>
<td>3.01</td>
<td>(2.22-4.06)</td>
<td>39</td>
<td>1.97</td>
<td>ND&lt;sup&gt;c&lt;/sup&gt;</td>
<td>43</td>
</tr>
<tr>
<td>GROUP 2&lt;sup&gt;b&lt;/sup&gt;</td>
<td>N</td>
<td>Level</td>
<td>95% CI</td>
<td>12</td>
<td>12</td>
<td>ND</td>
<td>10</td>
<td>ND</td>
<td>12</td>
<td>12</td>
</tr>
<tr>
<td>N</td>
<td>12</td>
<td>0.14</td>
<td>(0.11-0.18)</td>
<td>12</td>
<td>3.78</td>
<td>(2.18-6.56)</td>
<td>1.21</td>
<td>ND</td>
<td>ND</td>
<td>0.76&lt;sup&gt;d&lt;/sup&gt;</td>
</tr>
<tr>
<td>Level</td>
<td>12</td>
<td>0.14</td>
<td>(0.11-0.18)</td>
<td>12</td>
<td>3.78</td>
<td>(2.18-6.56)</td>
<td>1.21</td>
<td>ND</td>
<td>ND</td>
<td>0.76&lt;sup&gt;d&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

<sup>*μg antibody/mL by RIA.</sup>
<sup><sup>a</sup>Group 1: Reimmunised at 27 months following primary immunisation.</sup>
<sup><sup>b</sup>Group 2: Reimmunised at 34 months following primary immunisation.</sup>
<sup><sup>c</sup>Not Done.</sup>
<sup><sup>d</sup>Antibody levels pre-reimmunization.</sup>
<sup><sup>e</sup>Includes available data from all reimmunized subjects (subjects initially randomized to TYPHIM Vi, and subjects initially randomized to placebo who received open label TYPHIM Vi two weeks later).</sup>

**INDICATIONS**

TYPHIM Vi is indicated for active immunisation against typhoid fever in subjects 2 years of age and over.

**CONTRAINDICATIONS**

Hypersensitivity to the vaccine or any component of the vaccine is a contraindication to use of this vaccine. TYPHIM Vi should not be given to anyone who is suffering or convalescing from an acute febrile illness.
PRECAUTIONS

Do not inject intravenously: ensure that the needle does not enter any blood vessel.

As with all injectable vaccines, appropriate medical treatment and supervision should always be readily available in case of rare anaphylactic reactions following the administration of the vaccine.

Individuals with impaired immune system, such as those with an immunosuppressive disease or receiving immunosuppressive drugs may not develop the expected antibody response to TYPHIM Vi.

Salmonella typhi Vi polysaccharide vaccine should be administered with caution to subjects with thrombocytopenia or bleeding disorders since bleeding may occur following an intramuscular administration to these subjects: following injection, firm pressure should be applied to the site (without rubbing) for at least 2 minutes.

Salmonella typhi Vi polysaccharide vaccine protects against typhoid fever caused by *Salmonella typhi*. Protection is not conferred against paratyphoid fever or illness caused by non-invasive Salmonellae. The importance of scrupulous attention to personal, food and water hygiene must be emphasised for all persons at risk of typhoid fever.

Vaccination should occur at least 2 weeks prior to potential exposure to infection with *Salmonella typhi*.

As with other vaccines, vaccination may not be expected to protect 100% of susceptible individuals (refer to pharmacology section).

USE IN PREGNANCY AND LACTATION (Category B2)

There is no convincing evidence of risk to the foetus from immunisation of pregnant women using inactivated virus vaccines, bacterial vaccines or toxoids. It is not known if TYPHIM Vi is secreted in human milk.

INTERACTIONS WITH OTHER MEDICINES

Available data support concomitant use of TYPHIM Vi with yellow fever vaccine in separate syringes at separate sites. Data concerning use with other vaccines are limited. However, no interaction is anticipated when vaccines are given at separate sites using separate syringes.

ADVERSE EFFECTS

Clinical Trials Experience
Adverse reactions from a trial in Indonesia investigating safety in children receiving TYPHIM Vi, aged 1 to 12 years, are summarised in Table 2.

### TABLE 2: PERCENTAGE OF INDONESIAN CHILDREN ONE TO TWELVE YEARS OF AGE PRESENTING WITH LOCAL OR SYSTEMIC REACTIONS WITHIN 48 HOURS AFTER THE FIRST IMMUNIZATION WITH TYPHIM Vi.

<table>
<thead>
<tr>
<th>REACTIONS</th>
<th>Number with Adverse Reactions (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Local</strong></td>
<td></td>
</tr>
<tr>
<td>Soreness</td>
<td>23 (13.0%)</td>
</tr>
<tr>
<td>Pain</td>
<td>25 (14.3%)</td>
</tr>
<tr>
<td>Erythema</td>
<td>12 (6.9%)</td>
</tr>
<tr>
<td>Induration</td>
<td>5 (2.9%)</td>
</tr>
<tr>
<td>Impaired Limb Use</td>
<td>0</td>
</tr>
<tr>
<td><strong>Systemic</strong></td>
<td></td>
</tr>
<tr>
<td>Feverishness (subjective)</td>
<td>5 (2.9%)</td>
</tr>
<tr>
<td>Headache</td>
<td>0</td>
</tr>
<tr>
<td>Decreased Activity</td>
<td>3 (1.7%)</td>
</tr>
</tbody>
</table>

In a U.S. Reimmunisation study, subjects who had received TYPHIM Vi 27 or 34 months earlier, and subjects who had never previously received a typhoid vaccination, were randomised to placebo or TYPHIM Vi, in a double blind study. In this study 5/30 (17%) primary immunisation subjects and 10/45 (22%) reimmunisation subjects had an objective local reaction (erythema and/or induration at the site of injection). No severe or unusual side effects were observed. Most subjects reported pain and/or tenderness (pain upon direct pressure). Local adverse experiences were generally limited to the first 48 hours. Results are summarised in Table 3.

### TABLE 3: U.S. REIMMUNIZATION STUDY, SUBJECTS PRESENTING WITH LOCAL AND SYSTEMIC REACTIONS WITHIN 48 HOURS AFTER IMMUNIZATION WITH TYPHIM Vi.

<table>
<thead>
<tr>
<th>REACTIONS</th>
<th>Placebo (N=32)</th>
<th>First Immunisation (N=30)</th>
<th>Reimmunisation (N=45*)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Local</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tenderness</td>
<td>2 (6%)</td>
<td>28 (93%)</td>
<td>44 (98%)</td>
</tr>
<tr>
<td>Pain (upon direct pressure)</td>
<td>1 (3%)</td>
<td>13 (43%)</td>
<td>25 (56%)</td>
</tr>
<tr>
<td>Induration</td>
<td>0</td>
<td>5 (17%)</td>
<td>8 (18%)</td>
</tr>
<tr>
<td>Erythema</td>
<td>0</td>
<td>1 (3%)</td>
<td>5 (11%)</td>
</tr>
<tr>
<td><strong>Systemic</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Malaise</td>
<td>1 (3%)</td>
<td>11 (37%)</td>
<td>11 (24%)</td>
</tr>
<tr>
<td>Headache</td>
<td>5 (16%)</td>
<td>8 (27%)</td>
<td>5 (11%)</td>
</tr>
<tr>
<td>Myalgia</td>
<td>0</td>
<td>2 (7%)</td>
<td>1 (2%)</td>
</tr>
<tr>
<td>Nausea</td>
<td>0</td>
<td>1 (3%)</td>
<td>1 (2%)</td>
</tr>
<tr>
<td>Diarrhoea</td>
<td>0</td>
<td>0</td>
<td>1 (2%)</td>
</tr>
</tbody>
</table>
Feverish (subjective) | 0 | 3 (10%) | 2 (4%)
Fever ≥ 38°C | 1 (3%) | 0 | 1 (2%)
Vomiting | 0 | 0 | 0

*At 27 or 34 months following a previous dose given in different studies.

Post-Marketing Reports

The following adverse reactions have been reported in the post-marketing experience to date:

Very common: \( \geq 1/10 \) (\( \geq 10\% \))
Common: \( \geq 1/100 \) and \( < 1/10 \) (\( \geq 1\% \) and \( <10\% \))
Uncommon: \( \geq 1/1000 \) and \( <1/100 \) (\( \geq 0.1\% \) and \( <1\% \))
Rare: \( \geq 1/10000 \) and \( <1/1000 \) (\( \geq 0.01\% \) and \( <0.1\% \))
Very rare: \( < 1/10000 \) (\( <0.01\% \))

Application site disorders (local reactions at the site of injection):
Very rare: Pain
Oedema
Redness

Body as a whole:
Very rare: Fever
Headache
Malaise
Fatigue
Serum sickness
Anaphylactoid reactions
Allergic type reactions (unspecified)

Skin and Appendages Disorders:
Very rare: Rash
Pruritus
Urticaria

Gastrointestinal Disorders:
Very rare: Nausea
Vomiting
Diarrhoea
Abdominal pain

Musculo-skeletal:
Very rare: Arthralgia
Myalgia

Respiratory System Disorders:
Very rare: Asthma
DOSAGE AND ADMINISTRATION

A single dose of 0.5 mL for adults is given intramuscularly in the deltoid, and the dose for children is given intramuscularly either in the deltoid or the vastus lateralis. The vaccine should not be injected into the gluteal area or areas where there may be a nerve trunk.

The prefilled syringe is for use in a single patient only and any residue must be discarded.

The vaccination dose is the same for adults and children.

TYPHIM Vi should be administered at least 14 days prior to potential exposure to infection with Salmonella typhi.

A reimmunising dose is 0.5 mL. An optimal reimmunisation schedule has not been established. Reimmunisation consisting of a single dose every two to three years for individuals under conditions of repeated or continued exposure to the S. typhi organism is recommended at this time.

OVERDOSAGE

There is no data on overdose of TYPHIM Vi.

PRESENTATION AND STORAGE CONDITIONS

Presentation
Single dose pre-filled syringe, unit pack.

Storage
Store at 2°C-8°C. Refrigerate. Do not freeze. Product that has been exposed to freezing should not be used. Do not use after expiration date.

NAME AND ADDRESS OF THE SPONSOR

Australia:
sanofi-aventis australia pty ltd
Talavera Corporate Centre - Building D
12 - 24 Talavera Road
Macquarie Park NSW 2113
Australia
Tel: 1800 829 468

New Zealand:
sanofi-aventis new zealand limited
POISON SCHEDULE OF THE MEDICINE

S4 – Prescription Only Medicine

DATE OF FIRST INCLUSION IN THE AUSTRALIAN REGISTER OF THERAPEUTIC GOODS (ARTG)

09 October 2000

DATE OF MOST RECENT AMENDMENT

01 February 2013